Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.
10.3802/jgo.2009.20.3.169
- Author:
Jongyun HWANG
1
;
Sunghun NA
;
Hyangah LEE
;
Dongheon LEE
Author Information
1. Department of Obstetrics and Gynecology, Kangwon National University Medical School, Chuncheon, Korea. obypf@kangwon.ac.kr
- Publication Type:Original Article
- Keywords:
Ovarian cancer biomarkers;
Leptin;
Prolactin;
Osteopontin;
Insulin-like growth factor-II;
CA-125
- MeSH:
Biomarkers;
Enzyme-Linked Immunosorbent Assay;
Humans;
Leptin;
Mass Screening;
Neoplasms, Glandular and Epithelial;
Osteopontin;
Ovarian Neoplasms;
Prolactin;
Proteins;
Biomarkers, Tumor
- From:Journal of Gynecologic Oncology
2009;20(3):169-175
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To examine the correlation among the preoperative serum levels of five biomarkers presumed to be useful for early detection of epithelial ovarian cancer and evaluate the relationships between serum levels of these five biomarkers and epithelial ovarian cancer stage. METHODS: We analyzed 56 newly diagnosed epithelial ovarian cancer patients. Preoperative serum levels of leptin, prolactin, osteopontin (OPN), insulin-like growth factor-II, and CA-125 were determined by ELISA. We also examined the correlation between the serum levels of the biomarkers and ovarian cancer stage. Significant differences in the mean serum levels of two proteins, leptin and CA-125, were observed between stage subsets. RESULTS: There was a significant negative correlation between prolactin and leptin and a significant positive correlation between prolactin and OPN. Of the five biomarkers, only the mean serum CA-125 level showed a significant positive correlation with cancer stage (Spearman rho=0.24, p<0.01). OPN showed a marginally significant positive correlation with stage (Spearman rho=0.14, p=0.07). CONCLUSION: We demonstrated the relationship between five biomarkers in epithelial ovarian cancer. These tumor markers may be useful in screening for ovarian cancer, in characterizing disease states, and in developing therapeutic interventions targeting these marker proteins. Large-scale studies that include potential confounding factors and modifiers are necessary to more accurately define the value of these novel biomarkers in ovarian cancer.
